表紙
市場調査レポート

麻酔効果:パイプライン製品の分析

Anesthetic Effect - Pipeline Review, H1 2016

発行 Global Markets Direct 商品コード 253649
出版日 ページ情報 英文 94 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.75円で換算しております。
Back to Top
麻酔効果:パイプライン製品の分析 Anesthetic Effect - Pipeline Review, H1 2016
出版日: 2016年04月13日 ページ情報: 英文 94 Pages
概要

麻酔効果、意識の喪失の合併症のリスクを高める主な要因要因として、喫煙や閉塞型睡眠時無呼吸症、肥満、高血圧、麻酔の副作用の病歴、医薬品へのアレルギー体質などが挙げられます。

当レポートでは、世界各国での麻酔効果治療用のパイプライン製品の開発状況について分析し、製品開発・上市の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などの情報をお届けします。

イントロダクション

  • 調査範囲

麻酔効果の概要

治療薬の開発

  • パイプライン製品の概要
  • パイプライン製品の比較分析

麻酔効果:企業で開発中の治療薬

麻酔効果:大学/機関で研究中の治療薬

麻酔効果:パイプライン製品の概況

  • 後期段階の製品
  • 臨床段階の製品
  • 初期段階の製品
  • 開発段階が不明の製品

麻酔効果:企業で開発中の製品

麻酔効果:大学/機関で研究中の製品

麻酔効果の治療薬開発に従事している企業

  • Advicenne Pharma
  • Biolab Sanus Farmaceutica Ltda.
  • Drawbridge Pharmaceuticals Pty Ltd
  • Jiangsu Hengrui Medicine Co., Ltd.
  • Juniper Pharmaceuticals, Inc.
  • Laboratoires Thea S.A.
  • Lipicard Technologies Limited
  • Merck & Co., Inc.
  • NanoMedex Pharmaceuticals, Inc.
  • Paion AG
  • Phosphagenics Limited
  • Physica Pharma SAS
  • Proteus SA
  • Sphaera Pharma Pvt. Ltd.
  • Taiwan Liposome Company, Ltd.
  • The Medicines Company

麻酔効果:治療薬の評価

  • 単剤製品
  • 併用製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

麻酔効果:最近のパイプライン動向

麻酔効果:休止中のプロジェクト

麻酔効果:開発が中止された製品

麻酔効果:製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC7852IDB

Summary

Global Markets Direct's, 'Anesthetic Effect - Pipeline Review, H1 2016', provides an overview of the Anesthetic Effect pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Anesthetic Effect, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Anesthetic Effect and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Anesthetic Effect
  • The report reviews pipeline therapeutics for Anesthetic Effect by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Anesthetic Effect therapeutics and enlists all their major and minor projects
  • The report assesses Anesthetic Effect therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Anesthetic Effect

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Anesthetic Effect
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Anesthetic Effect pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Herpes Zoster (Shingles) Overview
  • Therapeutics Development
    • Pipeline Products for Herpes Zoster (Shingles) - Overview
  • Herpes Zoster (Shingles) - Therapeutics under Development by Companies
  • Herpes Zoster (Shingles) - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
    • Unknown Stage Products
  • Herpes Zoster (Shingles) - Products under Development by Companies
  • Herpes Zoster (Shingles) - Companies Involved in Therapeutics Development
    • Astellas Pharma Inc.
    • Beijing Minhai Biotechnology Co., Ltd
    • ContraVir Pharmaceuticals, Inc.
    • Epiphany Biosciences, Inc.
    • Foamix Pharmaceuticals Ltd.
    • GeneOne Life Science, Inc.
    • GlaxoSmithKline Plc
    • Merck & Co., Inc.
    • NAL Pharmaceuticals Ltd.
    • ReceptoPharm, Inc.
    • TSRL, Inc.
  • Herpes Zoster (Shingles) - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • acyclovir - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • amenamevir - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • FV-100 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • GLS-5100 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • GSK-1437173A - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • herpes zoster vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • NAL-3221 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • NAL-3223 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • RPI-78M - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TSR-087 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • V-212 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • valomaciclovir stearate - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Herpes Zoster (Shingles) - Recent Pipeline Updates
  • Herpes Zoster (Shingles) - Dormant Projects
  • Herpes Zoster (Shingles) - Discontinued Products
  • Herpes Zoster (Shingles) - Product Development Milestones
    • Featured News & Press Releases
      • Mar 03, 2016: ContraVir Pharmaceuticals Reports Positive Results Confirming the Safety of its Shingles Candidate FV-100 in a Drug-Drug Interaction Study
      • Oct 27, 2015: GSK's candidate shingles vaccine demonstrates 90% efficacy against shingles in people 70 years of age and over
      • Sep 08, 2015: Clinical trial for Cardiff's shingles treatment
      • Aug 03, 2015: ContraVir Pharmaceuticals Enrolls First Patient in Pivotal Phase 3 Study of FV-100 for Treatment of Shingles and Shingles-Associated Pain
      • Jun 09, 2015: ContraVir Pharmaceuticals Selects ImageIQ as Imaging CRO for Phase III Clinical Trial
      • Apr 28, 2015: GSK candidate vaccine for the prevention of shingles demonstrates overall efficacy of 97.2% which does not diminish in the age groups studied
      • Mar 09, 2015: ContraVir Pharmaceuticals to Initiate Pivotal Phase 3 Study of FV-100 for Prevention of Shingles-Associated PHN
      • Dec 18, 2014: Pivotal phase III study of GSK shingles candidate vaccine meets its primary endpoint
      • Dec 18, 2014: Positive Outcome of Phase 3 Study of GSK Shingles Vaccine Containing Agenus Adjuvant
      • Dec 09, 2014: ContraVir Pharmaceuticals Initiates Pharmacokinetic Study of Lead Antiviral FV-100 for Treating Shingles
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Herpes Zoster (Shingles), H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Comparative Analysis by Unknown Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Herpes Zoster (Shingles) - Pipeline by Astellas Pharma Inc., H1 2016
  • Herpes Zoster (Shingles) - Pipeline by Beijing Minhai Biotechnology Co., Ltd, H1 2016
  • Herpes Zoster (Shingles) - Pipeline by ContraVir Pharmaceuticals, Inc., H1 2016
  • Herpes Zoster (Shingles) - Pipeline by Epiphany Biosciences, Inc., H1 2016
  • Herpes Zoster (Shingles) - Pipeline by Foamix Pharmaceuticals Ltd., H1 2016
  • Herpes Zoster (Shingles) - Pipeline by GeneOne Life Science, Inc., H1 2016
  • Herpes Zoster (Shingles) - Pipeline by GlaxoSmithKline Plc, H1 2016
  • Herpes Zoster (Shingles) - Pipeline by Merck & Co., Inc., H1 2016
  • Herpes Zoster (Shingles) - Pipeline by NAL Pharmaceuticals Ltd., H1 2016
  • Herpes Zoster (Shingles) - Pipeline by ReceptoPharm, Inc., H1 2016
  • Herpes Zoster (Shingles) - Pipeline by TSRL, Inc., H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Herpes Zoster (Shingles) Therapeutics - Recent Pipeline Updates, H1 2016
  • Herpes Zoster (Shingles) - Dormant Projects, H1 2016
  • Herpes Zoster (Shingles) - Discontinued Products, H1 2016

List of Figures

  • Number of Products under Development for Herpes Zoster (Shingles), H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Targets, H1 2016
  • Number of Products by Stage and Targets, H1 2016
  • Number of Products by Mechanism of Actions, H1 2016
  • Number of Products by Stage and Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Types, H1 2016
Back to Top